Abstract: A vaccine preparation comprising in combination a vaccine and a toxin or subunit thereof as an effective component. The toxin is preferably a bacterial toxin, e.g. cholera toxin, staphylococcal .alpha.-hemolysin, staphylococcal .delta.-hemolysin, vibrio thermostable direct hemolysin, pertussis toxin or E. coli heat-labile toxin. The toxin can be a B subunit or a part of a B subunit of a toxin. The vaccine can be influenza vaccine, pertussis vaccine, Japanese encephalitis vaccine, mixed vaccine of pertussis, diphtheria and tetanus toxoid, hepatitis B vaccine, rota vaccine, measles vaccine, rubella vaccine, mumps vaccine, combined vaccine of measles, rubella and mumps, or mycoplasma vaccine. The ratio of vaccine to toxin or subunit thereof is 1:0.0001-1:10,000 (w/v). The vaccine can be intranasal vaccine, or can be in injectable form, spray form or oral administration form.

Abstract: Method for specifically cleaving a single stranded DNA molecule. The method includes providing an RNA molecule having a deoxyribonuclease activity independent of any protein, and contacting that RNA molecule with the single stranded DNA molecule to cause the single stranded DNA molecule to be cleaved.

Abstract: The present invention relates to a method for quantitatively assaying the presence of DSP toxins such as okadaic acid and dinophysistoxin-1 in marine samples. The method comprises the steps of preparing a marine extract, fractionating the prepared marine extract and selecting the extract fraction containing the toxin to be assayed. Once the desired extract fraction has been selected, a labelled substrate for protein phosphatase and at least one protein phosphatase are added to the extract in an assay. The amount of toxin present is quantitatively measured by the ability of the extract fraction to inhibit catalysis, mainly dephosphorylation, of the labelled substrate by protein phosphatases, such as phosphatase-1 (PP1) or phosphatase-2A (PP2A). Preferably, the method of the present invention is used to assay the presence of okadaic acid in marine organisms such as mussels, oysters, scallops, phytoplankton and the like.

Abstract: Disclosed is a vaccine for the prevention of disease caused by canine distemper virus (CDV). The vaccine is prepared from CDV immunogens derived from CDV persistently-infected cells cultured in vitro. CCL-64 mink lung cells are the preferred cell line. CDV persistently-infected cells are cultured in serum-containing growth medium, the cells transferred and maintained in serum-free medium under conditions and for a time adequate to accumulate in said serum-free medium said CDV immunogens, and the cells separated from said CDV immunogen-containing supernatant. The CDV vaccine is made by diluting said supernatent and blending with a pharmaceutically-acceptable adjuvant.

Abstract: N4-(3-phenylproprionyl)-2'-deoxycytidine derivatives are disclosed having the following formula: ##STR1## wherein R.sup.1 is --CO--CH.sub.2 --CH.sub.2 --C.sub.6 H.sub.5, R.sup.5 is hydrogen, a trityl group or the group --CO--CH.sub.2 --CH.sub.2 --C.sub.6 H.sub.5, R.sup.6 is selected from the group consisting of hydrogen, --CO--CH.sub.2 --CH.sub.2 --C.sub.6 H.sub.5, ##STR2## and R.sup.7 is hydrogen or OH. These derivatives are useful in oligonucleotide synthesis because the 3-phenyl-proprionyl blocking group can be removed rapidly by ammonia.

Abstract: The invention features herbal extracts from ten (10) Chinese Herbal Medicines demonstrating significant in vitro and ex vivo anti-HIV activity and their use for the diagnosis and treatment of HIV and HIV-related disease.

Abstract: Polycyclic mutagens are removed from aqueous or organic solutions by contacting the solution with a grafted dextranomer adsorbent which contains hydroxypropyl groups covalently linked to a reactive phthalocyanine dye.

Abstract: A process of making oligoribonucleoside and deoxyribonucleoside boranophosphates and salts thereof is disclosed. The process comprises the steps of condensing a ribonucleotide or deoxyribonucleotide with a nucleoside phosphitylating agent, wherein the phosphitylating agent includes a 5' -OH group protected by an acid-labile protecting group and a moiety bonded to the phosphorus atom therein that is a stronger proton acceptor than the 5'-OH group of the ribonucleotide or deoxyribonucleotide to form a reaction intermediate, then oxidizing the reaction intermediate so formed with a compound comprising a Lewis base and a boron-containing substituent, wherein the Lewis base is a weaker electron donor than the phosphite phosphorus of the reaction intermediate, to form a ribonucleotide or deoxyribonucleotide boranophosphate. These steps are repeated on the nucleotide boranophosphate to form an oligonucleotide boranophosphate.

Abstract: A composition comprising either fructose or ribose, starch hydrolysate and a film forming agent other than starch hydrolysate is described. The composition, characterized by a weight ratio of fructose or ribose to starch hydrolysate in the range of between about 1:99 and about 15:85, is employed in a method of treating wounds in a host in need of such treatment. In this method a therapeutically effective amount of the composition contacts the wound for a period of time sufficient to initiate wound healing.

Abstract: A vaccine for protection against swine dysentery which comprises T. hyodysenteriae hemolysin and a physiologically acceptable vehicle for said peptide. The vaccine contains the hemolysin in an amount effective for protecting against swine dysentery. The invention also relates to a method of protecting swine against swine dysentery by administering to swine the vaccine described above.

Abstract: A preparation for treating immune complex diseases which comprises injection containing the following compound: ##STR1## wherein when n is 1, Z represents a hydrogen, lithium, potassium, sodium, ammonium or organic ammonium, and when n is 2, Z represents calcium, barium or magnesium, as an active ingredient and pharmacologically acceptable carrier. The preparation of the present invention may be used in any administration method such as hypodermic, intramuscular and intravenous.

Abstract: A process for stabilizing a composition containing an anionic surfactant by using a cationized xanthan gum, a stabilizer for the composition containing an anionic surfactant which contains a cationized xanthan gum as a component, and a anionic surfactant-containing composition stabilized by inclusion of a cationized xanthan gum.

Abstract: A stable immunogen composition for oral administration which includes a dried spherical form comprised of an immunogen capable of immunizing human or animals and a gelatin having an average molecular weight of 80,000-120,000 and jelly strength of more than 150 (Bloom, g, 6.2/3%), and is enteric.

Abstract: A polysaccharide (Biopolymer B-16) being produced by cultivating Alcaligenes latus strain B-16 (FERM-2015) and having at least one function selected from water absorption, moisture absorption, humectant capability, thickening capability, suspension stability, emulsion stability and dispersant capability along with high biodegradability and which can be used without creating any environmental hazard such as secondary pollution, said Biopolymer B-16 consisting essentially of rhamnose, fucose, glucose, mannose and glucuronic acid which are present in a molar ratio of(1-10):(2-10):(4-20):(1):(1-5).

Abstract: A rapidly hydrating welan gum useful for preparing cementitious products. The gum can be dry blended with cement or other dry component and then added to a preformed cement/water pre-mix, thereby alleviating the need for hydrating the gum prior to addition to a cement/water mixture.

Abstract: A phytohormone for inducing root hair curling and root nodulation in the roots of leguminous plants particularly in the absence of nitrogen-fixing bacteria. The phytohormone comprises a pentassaccharide having a fatty acid condensed on the non-reducing end. a method for treating the roots of leguminous plants for inducing root hair curling and root nodulation is also disclosed.

Abstract: Disclosed are novel erythromycin derivatives, or salts thereof, represented by the following general formula: ##STR1## and processes for preparing the same. The erythromycin derivatives described above have an excellent effect of stimulating the gastrointestinal contractile motion and have low toxicity, and the preparations containing these compounds can be advantageously used as digestive tract contractile motion stimulants.

Abstract: Pyridinone or pyrimidinone nucleoside bases containing fused aromatic polycyclic rings are provided. These polycyclic nucleosides are incorporated into oligonucleotides and hybridized to complementary nucleic acid. Fluorescence spectroscopy and thermal denaturation profiles provided evidence that the polycyclic base is intercalated into the resulting duplex. The fused polycyclic ring systems optionally are substituted with reactive species which inactivate complementary nucleic acids. The oligonucleotides of this invention are useful as improved probes, diagnostic reagents, or for cleaving or derivatizing predetermined domains within nucleic acids.

Abstract: Test samples of genomic DNA may be characterized by the use of polynucleotide probes each of which is specific for an informative genetic locus. Such probes may be prepared by the use of probes which are capable of differentiating DNA by reference to more than one polymorphic minisatellite region or hypervariable locus. The polynucleotides and probes of the invention are of use for genetic identification purposes, paternity and maternity testing and particularly in forensic medicine.

Abstract: The present invention relates to novel ribonucleotide reductase inhibitors and new combinations comprising an antiviral compound, such as acyclovir, and a thiocarbonohydrazone ribonucleotide reductase inhibitor for the chemotherapeutic treatment of virus infections, espectially viruses of the herpes group.